Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27552704 | 0.81 | TDP1 (0.41) | TDP1HSD17B10MAPTIMPDH2SMN1; SMN2 | |
| SCHEMBL2635391 | 0.78 | MRGPRX4 (0.52) | TDP1HSD17B10MAPTMAPK1ALDH1A1 | |
| SCHEMBL28126408 | 0.77 | CYP1A2 (0.37) | HSD17B10ALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL8921714 | 0.77 | CYP1A2 (0.37) | HSD17B10ALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL979782 | 0.77 | HSD17B10 (0.51) | TDP1HSD17B10MAPTIMPDH2SMN1; SMN2 | |
| SCHEMBL11218412 | 0.77 | TDP1 (0.50) | TDP1HSD17B10MAPTSMN1; SMN2LMNA | |
| SCHEMBL20768513 | 0.76 | MRGPRX4 (0.37) | MAPTSMN1; SMN2LMNAALDH1A1KDM4E | |
| SCHEMBL19331448 | 0.76 | MYC (0.36) | ALDH1A1KDM4ETSHRHTT | |
| SCHEMBL28349639 | 0.76 | TDP1 (0.46) | TDP1HSD17B10MAPTSMN1; SMN2LMNA | |
| SCHEMBL30466426 | 0.75 | MAPT (0.68) | TDP1HSD17B10MAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859601-B2 | Substituted benzyl and phenylsulfonyl triazolones, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| EP-2411361-B1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8148525-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8138189-B2 | Substituted benzene compounds as modulators of the glucocorticoid receptor | HOFFMAN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20120045454-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| EP-2411361-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-20110245308-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-06 | — | — | US | disclosed |
| EP-1471915-B1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011100838-A1 | DERIVATIVES OF 1-PHENYL-1,5-DIHYDRO-BENZO[B] [1.4]DIAZEPINE-2.4-DIONE AS INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7906644-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-03-15 | — | — | US | disclosed |
| EP-2281563-A1 | 2,4-Pyrimidinediamine compounds and their uses | Rigel Pharmaceuticals, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010108902-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20100197918-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-4894386-A | ANTIINFLAMMATORY AGENTS | ICI AMERICAS INC. (US) | 1990-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045454-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | TDP1 1115/4885HSD17B10 4781/4885MAPT 4104/4885 |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, CRHR1 | TDP1 1284/4885HSD17B10 223/4885MAPT 2644/4885 |
| US-20100197918-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | FCER2, FCGR1A, FCGR2A | TDP1 1115/4885HSD17B10 4781/4885MAPT 4104/4885 |
| US-20110245308-A1 | SUBSTITUTED BENZYL AND PHENYLSULFONYL TRIAZOLONES, AND USE THEREOF | CHUK, BRSK2, IKBKE | TDP1 586/4885HSD17B10 2344/4885MAPT 4565/4885 |
| US-20110144330-A1 | 2,4-Pyrimidinediamine Compounds and their Uses | FCER2, FCGR1A, FCGR2A | TDP1 1115/4885HSD17B10 4781/4885MAPT 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.